The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

21 May 2020 16:05

RNS Number : 6687N
Tiziana Life Sciences PLC
21 May 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Tiziana Life Sciences Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Quilter plc

City and country of registered office (if applicable)

London, UK

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

18/05/2020

6. Date on which issuer notified (DD/MM/YYYY):

20/05/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Less than 5%

0.00%

Less than 5%

160,766,883

Position of previous notification (if

applicable)

17.40%

0.00%

17.40%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BKWNZY55

Less than 5%

Less than 5%

SUBTOTAL 8. A

Less than 5%

Less than 5%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Quilter plc

Quilter International Isle of Man Limited

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London, UK

Date of completion

20/05/2020

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUARVRROUVUAR
Date   Source Headline
2nd Mar 201812:09 pmRNSStatement re broker
22nd Jan 20187:00 amRNSPlacing
16th Jan 20187:00 amRNSPlacing
15th Dec 20177:00 amRNSPlacing and Issue of Equity
8th Dec 20177:00 amRNSMilciclib Phase 2a Trial Update
27th Nov 20177:00 amRNSPlacing
23rd Nov 20177:00 amRNSPhase II Clinical Trial Update
20th Nov 20177:00 amRNSSubscription
29th Sep 20177:00 amRNSInterim Results for Six Months Ended 30 June 2017
6th Sep 20177:00 amRNSA Proprietary Oral Formulation of Foralumab
31st Aug 201711:07 amRNSGrant of options - Director's dealing
16th Aug 20177:00 amRNSConversion of outstanding loan notes
28th Jul 20177:00 amRNSPublication of Research Article on Foralumab
19th Jul 20177:00 amRNSInitiation of a Phase IIa Clinical Trial
12th Jul 20177:00 amRNSProposed changes to CLNs and Warrant Terms
29th Jun 201711:21 amRNSResult of AGM
12th Jun 20177:00 amRNSAppointment of Dr Kunwar Shailubhai as CEO
8th Jun 201710:02 amRNSNOTIFICATION OF MAJOR INTEREST IN SHARES
8th Jun 20178:14 amRNSBcl-3 pre-clinical update and Director's dealing
1st Jun 20177:00 amRNS2016 Annual Report and Accounts and notice of AGM
23rd May 20177:00 amRNSFinancial Results for Year Ended 31 December 2016
24th Apr 20177:14 amRNSAnnounces Approval of a Phase II Clinical Trial
21st Apr 20177:00 amRNSAnnounces Publication of Milciclib Clinical Trial
24th Mar 20177:00 amRNSExercise of Warrants & Issue of Equity
14th Mar 20177:00 amRNSArun Sanyal appointed to Scientific Advisory Board
16th Jan 20177:00 amRNSWarrant Expiry - Reminder
3rd Jan 20177:00 amRNSTiziana Life Sciences in-licenses NI-1201
16th Nov 20167:00 amRNSNew Data with Foralumab
7th Nov 201612:29 pmRNSGrant of options
29th Sep 20167:00 amRNSHalf-year Report
15th Sep 20167:00 amRNSConfirmation of Capital Reduction
18th Aug 20167:00 amRNSChange of Registered Office
18th Jul 20167:00 amRNSTiziana acquires a unique bio-repository
30th Jun 201612:47 pmRNSResult of AGM
29th Jun 20167:00 amRNSIssue of Equity
10th Jun 201610:18 amRNSGrant of options and realisation bonus
7th Jun 20167:00 amRNSFinal Results
1st Jun 20167:00 amRNSPartnership with Cardiff Researchers Wins Award
19th May 20167:00 amRNSJournal review of anti - CD3 monoclonal antibodies
4th May 20167:00 amRNSAppointment of Dr. Robert Evans
28th Apr 20167:00 amRNSExercise of Warrants & Issue of Equity
4th Apr 20167:00 amRNSChief Financial Officer Appointed
15th Mar 20167:00 amRNSCo-Founder and NED Prof Chris McGuigan Passes Away
16th Feb 20164:40 pmRNSSecond Price Monitoring Extn
16th Feb 20164:35 pmRNSPrice Monitoring Extension
13th Jan 20167:00 amRNSFund raising
11th Jan 20167:00 amRNSDevelopment plans for foralumab & SAB appointments
8th Jan 20167:00 amRNSUpdate on Tiziana's Bcl-3 inhibitor
9th Dec 20158:00 amRNSAppoints James F. Tripp as Chief Operating Officer
8th Dec 20157:00 amRNSFund raising

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.